Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.48 |
| ▸ | AKT1 | P31749 | 7/20 | 0.48 |
| ▸ | MTOR | P42345 | 5/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | CIT | O14578 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | BUB1 | O43683 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369416 | 1.00 | PIK3CA (0.48) | PIK3CAAKT1MTORPIK3C3EPHB4 | |
| SCHEMBL21474450 | 1.00 | PIK3CA (0.48) | PIK3CAAKT1MTORPIK3C3EPHB4 | |
| SCHEMBL21474563 | 0.95 | AKT1 (0.46) | PIK3CAAKT1MTORPIK3C3EPHB4 | |
| SCHEMBL29369873 | 0.95 | AKT1 (0.46) | PIK3CAAKT1MTORPIK3C3EPHB4 | |
| SCHEMBL23438193 | 0.93 | PIK3CA (0.41) | PIK3CAAKT1MTORPIK3C3EPHB4 | |
| SCHEMBL21474451 | 0.80 | PIK3CA (0.49) | PIK3CAAKT1MTORPIK3C3EPHB4 | |
| SCHEMBL29369799 | 0.80 | PIK3CA (0.49) | PIK3CAAKT1MTORPIK3C3EPHB4 | |
| SCHEMBL21474462 | 0.79 | PIK3CA (0.47) | PIK3CAAKT1MTORPIK3C3EPHB4 | |
| SCHEMBL21474456 | 0.79 | PIK3CA (0.47) | PIK3CAAKT1MTORPIK3C3EPHB4 | |
| SCHEMBL29368928 | 0.79 | PIK3CA (0.47) | PIK3CAAKT1MTORPIK3C3EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774792-B1 | MORPHOLINE DERIVATES AS INHIBITORS OF VPS34 | NEUROPORE THERAPIES INC (US) | 2022-09-14 | — | — | EP | disclosed |
| US-11236079-B2 | Morpholine derivates as inhibitors of Vps34 | NEUROPORE THERAPIES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236079-B2 | Morpholine derivates as inhibitors of Vps34 | NEUROPORE THERAPIES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210163467-A1 | MORPHOLINE DERIVATES AS INHIBITORS OF VPS34 | NEUROPORE THERAPIES, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163467-A1 | MORPHOLINE DERIVATES AS INHIBITORS OF VPS34 | NEUROPORE THERAPIES, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2019199874-A1 | MORPHOLINE DERIVATES AS INHIBITORS OF VPS34 | NEUROPORE THERAPIES, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236079-B2 | Morpholine derivates as inhibitors of Vps34 | VPS35, TFEB, VPS4B | PIK3CA 114/4885AKT1 155/4885MTOR 52/4885 |
| US-20210163467-A1 | MORPHOLINE DERIVATES AS INHIBITORS OF VPS34 | VPS35, TFEB, VPS4B | PIK3CA 114/4885AKT1 155/4885MTOR 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.